926927-61-9 Usage
Description
VTX-2337 is a novel compound with potential therapeutic applications, characterized by its unique chemical structure and biological properties. It has been shown to modulate immune responses and exhibit antineoplastic effects, making it a promising candidate for various medical and pharmaceutical uses.
Uses
Used in Pharmaceutical Industry:
VTX-2337 is used as an immune modulator for its ability to stimulate the immune system and enhance the production of cytokines, such as TNF-α and IL-12, in human peripheral blood mononuclear cells (PBMCs), monocytes, and myeloid dendritic cells. This immune-stimulating property makes it a potential candidate for the development of new therapeutic agents targeting various diseases.
VTX-2337 is also used as an antineoplastic agent for its potential to reduce tumor growth and increase tumor infiltration of monocytes and T cells. Its combination with other therapeutic agents, such as pegylated liposomal doxorubicin (PLD), has shown promising results in preclinical models of ovarian cancer, indicating its potential use in cancer treatment.
References
1) Lu?et al.?(2012),?VTX-2337 is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC;?Clin. Cancer Res.?18?499
2) Lu?et al.?(2013),?TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells;?J. Immunother. Cancer?1?P44
3) Rutman?et al.?(2015),?Motolimod,a selective TLR8 agonist, induces apoptosis in monocytic myeloid-derived suppressor cells (M-MDSC);?J. Immunother. Cancer.?3?P296
4) Ferris?et al.?(2014),?Active8: a random, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN);?J. Immunother. Cancer?2P69
5) Monk?et al.?(2017),?Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-Immunotherapy;?Clin. Cancer Res.?23?1955
6) Dietsch?et al.?(2016),?Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity;?PLoS One?11?e0148764
Check Digit Verification of cas no
The CAS Registry Mumber 926927-61-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,6,9,2 and 7 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 926927-61:
(8*9)+(7*2)+(6*6)+(5*9)+(4*2)+(3*7)+(2*6)+(1*1)=209
209 % 10 = 9
So 926927-61-9 is a valid CAS Registry Number.
926927-61-9Relevant articles and documents
METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES
-
Page/Page column 42, (2010/06/11)
The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.
